findmyKOL
Clinical trialNCT02981914CompletedEarly phase 1Interventional

Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

SponsorUniversity of ChicagoEnrollment12Acute Myeloid LeukemiaB-cell Non-Hodgkin LymphomaClassical Hodgkin LymphomaMyelodysplastic Syndromes
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Chicago

    Chicago, Illinois, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 Mar 2017
Primary completion
9 Oct 2020
Completion
1 Nov 2020
Last update posted
22 Apr 2024
Registered enrollment
12
Registry id
NCT02981914

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.